CME Group (NASDAQ:CME) Stock Price Expected to Rise, TD Cowen Analyst Says

CME Group (NASDAQ:CME) had its target price boosted by investment analysts at TD Cowen from $328.00 to $340.00 in a report issued on Thursday,MarketScreener reports. The brokerage currently has a “buy” rating on the financial services provider’s stock. TD Cowen’s price target indicates a potential upside of 12.49% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Argus reissued a “hold” rating on shares of CME Group in a research note on Wednesday, March 4th. Raymond James Financial lifted their price objective on shares of CME Group from $310.00 to $320.00 and gave the stock an “outperform” rating in a research report on Monday. Rothschild & Co Redburn lifted their price objective on shares of CME Group from $333.00 to $347.00 and gave the stock a “neutral” rating in a research report on Thursday, March 12th. Weiss Ratings raised shares of CME Group from a “buy (b+)” rating to a “buy (a-)” rating in a research report on Monday, March 2nd. Finally, Royal Bank Of Canada boosted their target price on shares of CME Group from $295.00 to $302.00 and gave the company a “sector perform” rating in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $307.88.

CME Group Trading Down 0.2%

CME opened at $302.26 on Thursday. The firm’s fifty day moving average is $306.06 and its two-hundred day moving average is $284.06. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.03 and a current ratio of 1.03. The firm has a market cap of $108.40 billion, a PE ratio of 27.07, a price-to-earnings-growth ratio of 3.25 and a beta of 0.26. CME Group has a twelve month low of $251.90 and a twelve month high of $329.16.

CME Group (NASDAQ:CME) last announced its earnings results on Wednesday, February 4th. The financial services provider reported $2.77 EPS for the quarter, topping the consensus estimate of $2.75 by $0.02. The firm had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.64 billion. CME Group had a net margin of 62.45% and a return on equity of 14.65%. The business’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period last year, the company posted $2.52 EPS. Equities research analysts anticipate that CME Group will post 10.49 EPS for the current year.

Insider Buying and Selling

In related news, Director Bryan T. Durkin sold 4,200 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $309.65, for a total value of $1,300,530.00. Following the completion of the sale, the director owned 43,007 shares in the company, valued at $13,317,117.55. The trade was a 8.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Jonathan L. Marcus sold 3,291 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $333.37, for a total value of $1,097,120.67. Following the completion of the sale, the general counsel owned 7,192 shares of the company’s stock, valued at $2,397,597.04. The trade was a 31.39% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 8,539 shares of company stock worth $2,713,821 over the last quarter. 0.30% of the stock is owned by corporate insiders.

Institutional Trading of CME Group

Several hedge funds and other institutional investors have recently bought and sold shares of CME. Norges Bank bought a new stake in CME Group in the fourth quarter valued at approximately $1,523,241,000. Sanders Capital LLC bought a new stake in CME Group in the third quarter valued at approximately $1,006,932,000. Strive Asset Management LLC bought a new stake in CME Group in the third quarter valued at approximately $636,487,000. Victory Capital Management Inc. lifted its position in CME Group by 746.4% in the fourth quarter. Victory Capital Management Inc. now owns 2,049,649 shares of the financial services provider’s stock valued at $559,720,000 after purchasing an additional 1,807,491 shares during the last quarter. Finally, Life Cycle Investment Partners Ltd bought a new stake in CME Group in the fourth quarter valued at approximately $217,656,000. Institutional investors own 87.75% of the company’s stock.

CME Group News Roundup

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: Record Q1 volumes — CME reported international average daily volume (ADV) hit a record 11.4M contracts in Q1, up ~30% YoY, with all major product suites posting quarterly international ADV records; stronger ADV typically boosts transaction revenue and supports earnings durability. CME Group International ADV Reaches Record 11.4M Contracts in Q1 2026
• Positive Sentiment: Crypto product expansion — CME is adding Avalanche (AVAX) and Sui (SUI) futures (micro and standard sizes) with a planned May 4 rollout, and is advancing a broader 24/7 crypto offering; these moves expand addressable market and could lift future trading volumes and fees. CME Group to Launch Avalanche and Sui Futures
• Positive Sentiment: Analyst optimism — several broker notes surfaced: an average “Moderate Buy” consensus and a Raymond James note saying the stock is likely to rise, reflecting analyst confidence in CME’s revenue trends and product-led growth. CME Given Average Recommendation of Moderate Buy
• Positive Sentiment: Barclays raised its price target to $344 (from $312) — a material lift to modeled upside even as the firm kept an equal-weight rating, signaling higher long-term valuation assumptions. Barclays Adjusts Price Target on CME Group to $344
• Neutral Sentiment: New coverage and modest PTs — Keefe, Bruyette & Woods started coverage with a “market perform” and $305 target, a cautious near-term view that may limit upside from some investors. Keefe Bruyette & Woods Starts Coverage
• Neutral Sentiment: Macro/market flow context — CME’s market data is being widely cited (e.g., Fed-cut odds), and large block trades in oil and other futures routed through venues CME operates have driven episodic volatility and volume; this boosts ADV but can also cause short-term price swings in the stock. Markets Shift Toward Potential Fed Rate Cut; CME Data Cited
• Neutral Sentiment: Third‑party SPAC crypto financing references CME rates — an Evernorth SEC filing ties XRP pricing/valuation mechanics to CME CF rates, highlighting CME’s role in broader crypto market structure but with indirect and uncertain revenue implication. Evernorth Amended SEC Filing Deepens XRP Role
• Negative Sentiment: Regulatory/approval risk for crypto products — the AVAX and SUI futures launches are pending regulatory approval; any delays or restrictions could push out expected revenue gains and keep investor caution elevated. CME Group Launch Avalanche and Sui Futures

CME Group Company Profile

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.